CEL-SCI Corporation Stock NYSE
Stocks
US1508375086
Biotechnology & Medical Research
| Market Cap | 28.14M 24.16M 22.62M 20.71M 39.01M 2.69B 39.12M 268M 105M 1.35B 106M 103M 4.48B | P/E 2026 * |
-0.52x | P/E 2027 * | -0.25x |
|---|---|---|---|---|---|
| Enterprise Value | 22.59M 19.39M 18.15M 16.62M 31.31M 2.16B 31.4M 215M 84.03M 1.09B 84.81M 82.98M 3.6B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 3.82x |
| Free-Float |
93.73% | Yield 2026 * |
-
| Yield 2027 * | - |
| 23-07-18 | Wall Street sluit hoger | |
| 23-07-18 | Wall Street op winst | |
| 23-07-18 | Wall Street richting licht rode opening | |
| 23-07-18 | Futures voorspellen terughoudende opening Wall Street | |
| 21-06-28 | Cel-Sci presenteert positieve onderzoeksdata immunotherapie |
| 1 day | -0.36% |
| Manager | Title | Age | Since |
|---|---|---|---|
Geert Kersten
CEO | Chief Executive Officer | 67 | 1994-12-31 |
Patricia Prichep
DFI | Director of Finance/CFO | 75 | 2024-11-12 |
| Chief Tech/Sci/R&D Officer | - | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Geert Kersten
BRD | Director/Board Member | 67 | 1994-12-31 |
| Director/Board Member | 73 | 2015-06-21 | |
Bob Watson
CHM | Chairman | 69 | 2024-07-07 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.36% | -14.33% | - | - | 28.14M | |
| +3.31% | -3.70% | +61.03% | +103.64% | 70.64B | |
| +1.09% | +2.51% | +49.34% | +93.39% | 66.11B | |
| -1.03% | +0.46% | +8.14% | -5.28% | 27.98B | |
| -2.41% | -2.95% | -9.77% | +455.82% | 26.51B | |
| +0.59% | -0.39% | +63.66% | +12.27% | 26.44B | |
| +1.02% | +6.43% | +269.42% | +420.34% | 20.4B | |
| +0.37% | +1.21% | +36.55% | -15.78% | 20.17B | |
| -2.00% | -4.46% | +13.22% | +530.67% | 15.99B | |
| -1.50% | +2.92% | +43.50% | +151.30% | 13.69B | |
| Average | -0.09% | +0.99% | +59.45% | +194.04% | 31.99B | |
| Weighted average by Cap. | +0.71% | +0.65% | +56.49% | +154.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 5.97M 5.13M 4.8M 4.39M 8.28M 570M 8.3M 56.83M 22.22M 287M 22.42M 21.94M 951M |
| Net income | -25.08M -21.53M -20.16M -18.46M -34.77M -2.4B -34.87M -239M -93.31M -1.21B -94.18M -92.14M -4B | -29.51M -25.33M -23.72M -21.72M -40.91M -2.82B -41.03M -281M -110M -1.42B -111M -108M -4.7B |
| Net Debt | -5.55M -4.77M -4.46M -4.09M -7.7M -530M -7.72M -52.85M -20.66M -267M -20.85M -20.4M -885M | -5.34M -4.58M -4.29M -3.93M -7.4M -510M -7.42M -50.81M -19.86M -257M -20.05M -19.61M -851M |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
